Compare MNSO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNSO | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2020 | 2020 |
| Metric | MNSO | LEGN |
|---|---|---|
| Price | $19.84 | $22.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $24.10 | ★ $69.58 |
| AVG Volume (30 Days) | 678.0K | ★ 2.6M |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $2,795,603,723.00 | $909,045,000.00 |
| Revenue This Year | $27.64 | $68.83 |
| Revenue Next Year | $19.31 | $51.27 |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | 23.44 | ★ 74.75 |
| 52 Week Low | $13.95 | $21.19 |
| 52 Week High | $27.71 | $45.30 |
| Indicator | MNSO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 30.88 |
| Support Level | $19.35 | $21.19 |
| Resistance Level | $20.34 | $28.97 |
| Average True Range (ATR) | 0.35 | 1.23 |
| MACD | 0.10 | -0.13 |
| Stochastic Oscillator | 62.92 | 16.97 |
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand, which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from the MINISO brand segment. Geographically, it derives a majority of its revenue from China.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.